Evidence map›Paper›PMID 28025493›Full record

ArticleInternational journal of molecular sciences2016

Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3.

Tomoyoshi Komiyama, Atsushi Ogura, Takatsugu Hirokawa, Miao Zhijing, Hiroshi Kamiguchi, Satomi Asai, Hayato Miyachi, Hiroyuki Kobayashi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tomoyoshi KomiyamaDepartment of Clinical Pharmacology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. komiyama@tokai-u.jp.
Atsushi OguraNagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan. aogu@whelix.info.
Takatsugu HirokawaThe National Institute of Advanced Industrial Science and Technology (AIST), Tokyo Waterfront Bio-IT Research Building 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan. t-hirokawa@aist.go.jp.
Miao ZhijingDepartment of Clinical Pharmacology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. mrprince329@yahoo.co.jp.
Hiroshi KamiguchiSupport Center for Medical Research and Education, Tokai University, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. kamiguti@is.icc.u-tokai.ac.jp.
Satomi AsaiDepartment of Laboratory Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. sa@is.icc.u-tokai.ac.jp.
Hayato MiyachiDepartment of Laboratory Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. miyachi@is.icc.u-tokai.ac.jp.
Hiroyuki KobayashiDepartment of Clinical Pharmacology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. hkobayas@is.icc.u-tokai.ac.jp.
Tokai University · JPNagahama Institute of Bio-Science and Technology · JPNational Institute of Advanced Industrial Science and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene alterations are a well-established mechanism leading to drug resistance in acute leukemia cells. A full understanding of the mechanisms of drug resistance in these cells will facilitate more effective chemotherapy. In this study, we investigated the mechanism(s) of drug resistance in the human acute leukemia cell line MOLT-3 and its idarubicin-resistant derivative MOLT-3/IDR through complete mitochondrial and nuclear DNA analyses. We identified genetic differences between these two cell lines. The ND3 mutation site (p.Thr61Ile) in the mitochondrial DNA sequence was unique to MOLT-3/IDR cells. Moreover, we identified five candidate genes harboring genetic alterations, including

Indexed as

Polymorphism, GeneticAntibiotics, AntineoplasticCell Line, TumorCodon, TerminatorDNA, MitochondrialDrug Resistance, NeoplasmExonsHumansIdarubicinMutation, MissenseN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseAntibiotics, AntineoplasticCodon, TerminatorDNA, MitochondrialIdarubicinN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseCGH arrayGALNT2 genegene polymorphismgenetic variationsidarubicin (IDR)leukemiamitochondrial DNAMOLT-3

Identifiers

PMID28025493
PMCPMC5297647
OpenAlexW2562099966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.